Barclays’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.9M | Buy |
622,235
+490,200
| +371% | +$8.55M | ﹤0.01% | 1106 |
|
|
2025
Q1 | $1.66M | Sell |
132,035
-26,145
| -17% | -$329K | ﹤0.01% | 2154 |
|
|
2024
Q4 | $1.67M | Buy |
158,180
+46,514
| +42% | +$491K | ﹤0.01% | 2332 |
|
|
2024
Q3 | $1.62M | Buy |
111,666
+73,127
| +190% | +$1.06M | ﹤0.01% | 2331 |
|
|
2024
Q2 | $328K | Buy |
38,539
+8,666
| +29% | +$73.8K | ﹤0.01% | 2773 |
|
|
2024
Q1 | $306K | Sell |
29,873
-10,501
| -26% | -$108K | ﹤0.01% | 3118 |
|
|
2023
Q4 | $222K | Buy |
40,374
+22,597
| +127% | +$124K | ﹤0.01% | 3460 |
|
|
2023
Q3 | $66K | Sell |
17,777
-2,683
| -13% | -$9.96K | ﹤0.01% | 3475 |
|
|
2023
Q2 | $138K | Sell |
20,460
-15,322
| -43% | -$103K | ﹤0.01% | 3258 |
|
|
2023
Q1 | $232K | Buy |
35,782
+14,972
| +72% | +$97.1K | ﹤0.01% | 3062 |
|
|
2022
Q4 | $177K | Buy |
20,810
+825
| +4% | +$7.02K | ﹤0.01% | 3152 |
|
|
2022
Q3 | $106K | Sell |
19,985
-912
| -4% | -$4.84K | ﹤0.01% | 3402 |
|
|
2022
Q2 | $89K | Buy |
20,897
+3,792
| +22% | +$16.2K | ﹤0.01% | 3515 |
|
|
2022
Q1 | $60K | Buy |
+17,105
| New | +$60K | ﹤0.01% | 3927 |
|